Long-term use of ozanimod in patients with moderately to severely active ulcerative colitis

被引：0
|
作者：
Danese, S. [1 ]
Colombel, J-F [2 ]
Ponich, T. [9 ]
Jovanovic, I. [10 ]
Bossuyt, P. [11 ]
Longman, R. [3 ]
Alekseeva, O. [12 ]
Petersen, A. K. [4 ]
Marta, C. [4 ]
Charles, L. [4 ]
Sparrow, M. [13 ]
Rubin, D. T. [5 ]
Afzali, A. [6 ]
Loftus, E. V., Jr. [7 ]
Wolf, D. C. [8 ]
机构：
[1] IRCCS San Raffaele Hosp, Milan, Italy
[2] Icahn Sch Med Mt Sinai, New York, NY 10029 USA
[3] Weill Cornell Med, Jill Roberts Ctr Inflammatory Bowel Dis, New York, NY USA
[4] Bristol Myers Squibb, Princeton, NJ USA
[5] Univ Chicago, Med Inflammatory Bowel Dis Ctr, Chicago, IL USA
[6] Ohio State Univ, Wexner Med Ctr, Columbus, OH USA
[7] Mayo Clin, Div Gastroenterol & Hepatol, Coll Med, Rochester, MN USA
[8] Atlanta Gastroenterol Assoc, Ctr Crohns Dis & Ulcerat Colitis, Atlanta, GA USA
[9] Western Univ, London, ON, Canada
[10] Univ Hosp Med Ctr Bezanijska Kosa, Div Gastroenterol, Belgrade, Serbia
[11] Imelda Gen Hosp, Imelda GI Clin Res Ctr, Bonheiden, Belgium
[12] Nizhny Novgorod Reg Clin Hosp, Nizhnii Novgorod, Russia
[13] Monash Univ, Alfred Hosp, Melbourne, Vic, Australia
来源：
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY | 2022年 / 37卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
89
引用
收藏
页码：125 / 126
页数：2
相关论文
共 50 条
  • [31] Vedolizumab for the Treatment of Moderately to Severely Active Ulcerative Colitis
    Dulai, Parambir S.
    Mosli, Mahmoud
    Khanna, Reena
    Levesque, Barrett G.
    Sandborn, William J.
    Feagan, Brian G.
    PHARMACOTHERAPY, 2015, 35 (04): : 412 - 423
  • [32] Early dose optimization of golimumab induces late response and long-term clinical benefit in moderately to severely active ulcerative colitis
    Taxonera, Carlos
    Iborra, Marisa
    Maia Bosca-Watts, Marta
    Rubio, Saioa
    Nantes, Oscar
    Higuera, Rebeca
    Bertoletti, Federico
    Martinez-Montiel, Pilar
    Sierra-Ausin, Monica
    Mancenido, Noemi
    Lazar Perez-Calle, Jose
    Algaba, Alicia
    Olivares, David
    Alba, Cristina
    CURRENT MEDICAL RESEARCH AND OPINION, 2019, 35 (07) : 1297 - 1304
  • [33] Safety, Efficacy, and Pharmacokinetics of Golimumab in Patients with Moderately to Severely Active Ulcerative Colitis: PURSUIT-SC Long term Extension
    Reinisch, Walter
    Gibson, Peter R.
    Sandborn, William
    Feagan, Brian G.
    Marano, Colleen
    Strauss, Rick
    Johanns, Jewel
    Zhang, Hongyan
    Padgett, Lakshmi
    Adedokun, Omoniyi J.
    Colombel, Jean-Frederic
    Collins, Judith
    Rutgeerts, Paul J.
    Tarabar, Dino
    GASTROENTEROLOGY, 2016, 150 (04) : S776 - S777
  • [34] Matching-adjusted indirect comparisons of efficacy outcomes between etrasimod and ozanimod for moderately to severely active ulcerative colitis
    Jairath, Vipul
    Raine, Tim
    Leahy, Thomas P.
    Potluri, Ravi
    Wosik, Karolina
    Gruben, David
    Cappelleri, Joseph C.
    Hur, Peter
    Bartolome, Lauren
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2025, 14 (04)
  • [35] Efficacy and safety of adalimumab in Japanese patients with moderately to severely active ulcerative colitis
    Yasuo Suzuki
    Satoshi Motoya
    Hiroyuki Hanai
    Takayuki Matsumoto
    Toshifumi Hibi
    Anne M. Robinson
    Nael M. Mostafa
    Jingdong Chao
    Vipin Arora
    Anne Camez
    Roopal B. Thakkar
    Mamoru Watanabe
    Journal of Gastroenterology, 2014, 49 : 283 - 294
  • [36] Integrated summary of safety of obefazimod for patients with moderately to severely active ulcerative colitis
    Vermeire, S.
    Peyrin-Biroulet, L.
    Danese, S.
    Dubinsky, M.
    Dulai, P. S.
    Tilg, H.
    Siegmund, B.
    Hisamatsu, T.
    Shan, K.
    Jacobstein, D.
    Cataldi, F.
    Rabbat, C.
    Sands, B. E.
    JOURNAL OF CROHNS & COLITIS, 2025, 19 : i1554 - i1555
  • [37] Efficacy and safety of adalimumab in Japanese patients with moderately to severely active ulcerative colitis
    Suzuki, Yasuo
    Motoya, Satoshi
    Hanai, Hiroyuki
    Matsumoto, Takayuki
    Hibi, Toshifumi
    Robinson, Anne M.
    Mostafa, Nael M.
    Chao, Jingdong
    Arora, Vipin
    Camez, Anne
    Thakkar, Roopal B.
    Watanabe, Mamoru
    JOURNAL OF GASTROENTEROLOGY, 2014, 49 (02) : 283 - 294
  • [38] Long-Term Safety and Efficacy of Golimumab in Patients With Moderately to Severely Active Ulcerative Colitis: Results From the PURSUIT-SC Maintenance Study Extension
    Gibson, Peter R.
    Reinisch, Walter
    Sandborn, William
    Feagan, Brian G.
    Marano, Colleen W.
    Strauss, Richard
    Johanns, Jewel
    Zhang, Hongyan
    Padgett, Lakshmi
    Colombel, Jean-Frederic
    Collins, Judith
    Rutgeerts, Paul J.
    GASTROENTEROLOGY, 2014, 146 (05) : S587 - S587
  • [39] Long-term safety and efficacy of golimumab in patients with moderately to severely active ulcerative colitis: Results from the PURSUIT-SC Maintenance study extension
    Reinisch, W.
    Gibson, P.
    Sandborn, W. J.
    Feagan, B. G.
    Marano, C.
    Strauss, R.
    Johanns, J.
    Zhang, H.
    Padgett, L.
    Colombel, J. -F.
    Collins, J.
    Rutgeerts, P.
    JOURNAL OF CROHNS & COLITIS, 2014, 8 : S6 - S7
  • [40] CLINICAL REMISSION DEMONSTRATED WITH ORAL OZANIMOD IN THE OVERALL POPULATION AND ACROSS MULTIPLE SUBGROUPS OF PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS IN THE TOUCHSTONE TRIAL
    Feagan, Brian G.
    Sandborn, William J.
    D'Haens, Geert R.
    Hanauer, Stephen B.
    Wolf, Douglas C.
    Vermeire, Severine
    Ghosh, Subrata
    Petersen, AnnKatrin
    Hua, Steven
    Shan, Kevin
    Liu, Jerry
    GASTROENTEROLOGY, 2019, 156 (06) : S1103 - S1104
12345